NCT01020214已完成1 期
Single-Dose Fasting Bioequivalence Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets (40 mg/25 mg; Mylan) to Benicar HCT® Tablets (40 mg/25 mg; Sankyo) in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- The 90% confidence interval for the LSMeans ratio of CPEAK, AUCL, and AUCI for the test and reference product should be between 80.00% and 125.00% for the natural log-transformed data.
研究概览
简要总结
The objective of this study was to investigate the bioequivalence of Mylan's olmesartan medoxomil and hydrochlorothiazide 40 mg/25 mg tablets to Sankyo's Benicar HCT® 40 mg/25 mg tablets following a single, oral 40 mg/25 mg (1 x 40 mg/25 mg) dose administered under fasting conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •healthy, adult subjects, 18 years and older
- •able to swallow medication
排除标准
- •institutionalized subjects
- •history of any significant disease
- •use of any prescription or OTC medications within 14 days of start of study
- •received any investigational products within 30 days prior to start of study
研究组 & 干预措施
1
Experimental
Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg
干预措施: Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg (Drug)
2
Active Comparator
Benicar HCT® Tablets 40 mg/25 mg
干预措施: Benicar HCT® Tablets 40 mg/25 mg (Drug)
结局指标
主要结局
The 90% confidence interval for the LSMeans ratio of CPEAK, AUCL, and AUCI for the test and reference product should be between 80.00% and 125.00% for the natural log-transformed data.
时间窗: blood collections through 48 hours
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Fasting Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mgHealthyNCT00649623Mylan Pharmaceuticals Inc36
已完成
1 期
Fed Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mgHealthyNCT01019590Mylan Pharmaceuticals Inc36
已完成
1 期
Fasting Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mgHealthyNCT00649077Mylan Pharmaceuticals Inc30
已完成
1 期
Fasting Study of Metolazone Tablets 10 mg and Zaroloxyn® Tablets 10 mgHealthyNCT00650195Mylan Pharmaceuticals Inc56
已完成
1 期
Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn® Tablets 5 mgHealthyNCT00649181Mylan Pharmaceuticals Inc52